Dr. Sam Sternberg discusses a novel CRISPR-Cas9 system using programmable, RNA-guided transposase, and highlights its implications for kilobase-scale genome engineering in cell and gene therapies.
The utility of programmable, RNA-guided CRISPR-Cas systems in genome engineering continues to evolve. Nature has afforded scientists novel and diverse gene editing functionality, from nuclease-dependent CRISPR-Cas9 to second-generation base and prime editors that do not produce double-strand breaks.
This webinar will describe a new CRISPR-Cas9 paradigm relying on nuclease-deficient bacterial transposons that catalyze RNA-guided integration of mobile genetic elements into the genome. The discovery of a fully programmable, RNA-guided transposase lays the foundation for kilobase-scale genome engineering with broad applications for developing cell and gene therapies.
Key Topics Include:
- The basics of first- and second-generation CRISPR-Cas technologies from a scientist at the forefront of their development
- Mechanisms, accommodation, and cell type diversity of CRISPR-Cas programmable transposition
- How transposase factor coordination enables highly specific, genome-wide DNA integration to target sites
- Implications of programmable transposases that obviate the need for DNA double-strand breaks and homologous recombination
Biochemistry and Molecular Biophysics